Trials / Terminated
TerminatedNCT02183805
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Detailed description
To explore the progression-free survival of patients with metastatic triple-negative breast cancer treated with peripheral blood stem cell transplant (PBSCT) followed by high dose chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abraxane,Cyclophosphamide,Carboplatin | High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin |
Timeline
- Start date
- 2014-06-17
- Primary completion
- 2020-12-15
- Completion
- 2020-12-15
- First posted
- 2014-07-08
- Last updated
- 2021-07-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02183805. Inclusion in this directory is not an endorsement.